Aspen Neuroscience Inc.

Aspen Neuroscience, Inc. (NASDAQ: ASPE - Get Free Report) Director Peter Thompson acquired 1,000,000 shares of the stock in a transaction dated Monday, November 2nd. The stock was bought at an average price of $15.00 per share, for a total transaction of $15,000,000.00. Following the completion of the purchase, the director owned 3,589,132 shares in the

Aspen Neuroscience, Inc. (NASDAQ: ASPE - Get Free Report) Director Peter Thompson acquired 1,000,000 shares of the stock in a transaction dated Monday, November 2nd. The stock was bought at an average price of $15.00 per share, for a total transaction of $15,000,000.00. Following the completion of the purchase, the director owned 3,589,132 shares in the

Three IPOs, one direct listing, and two SPACs priced during a challenging week for growth stocks. Just one SPAC is currently scheduled to list in the week ahead, although some smaller deals may also join the calendar throughout the week. Street research is expected for two companies in the week ahead, and six lock-up periods will be expiring.

SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Aspen Neuroscience, Inc. (Nasdaq: ASPE), a clinical-stage regenerative medicine biotechnology company developing autologous cell therapies for Parkinson's disease (PD), today announced the pricing of its initial public offering of 9,375,000 shares of common stock at a price to the public of $15.00 per share. All of the shares of common stock are being offered by Aspen.

Aspen Neuroscience is pursuing a $150 million IPO to fund Parkinson's Disease stem cell therapies. ASPE's lead candidate, sasineprocel, shows promising mid-stage efficacy but has procedure-related adverse events; FDA Fast Track and RMAT designations secured. Management is top-tier, backed by leading life science investors including Gilead Sciences; IPO valuation is reasonable at $258M enterprise value.